Riehen, Switzerland, June 14, 2022 – Ymmunobio AG a preclinical stage biotech
company specializing in the development of CEACAM (carcinoembryonic antigen-related cell
adhesion molecules) antibodies as anti-cancer treatments has signed a collaboration agreement with YUMAB for antibody based drug development projects.
Read Ymmunobio’s press release
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
Dr. Katrin Rupalla